RxDoctor Payments Data

Terri Hahn, MD

Internal Medicine · Stevens Point, WINPI 1265587976

Payments from drug & device makers

$926in general payments, 2019–2025

Across 21 payments — averaging $44.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$464
  • Actelion Pharmaceuticals US, Inc.$99
  • Biohaven Pharmaceutical Holding Company Ltd.$80
  • Inspire Medical Systems, Inc.$71
  • E.r. Squibb & Sons, L.L.C.$67
  • Sanofi-aventis U.S. LLC$64
  • plus $80 from 3 others

What the payments were for

  • Food & beverage$926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$926 in reported general payments places this provider in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$90,043
Medicare patients
801
Services billed
1,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban234$261,466
OzempicSemaglutide145$167,980
JardianceEmpagliflozin108$117,333
Teriparatide34$96,891
Humira(Cf)Adalimumab13$82,246
TrulicityDulaglutide62$78,314
XareltoRivaroxaban43$47,826
FarxigaDapagliflozin Propanediol34$34,795
MyrbetriqMirabegron39$32,843
LinzessLinaclotide22$27,546
MounjaroTirzepatide20$25,531
MultaqDronedarone Hcl18$24,176
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$23,247
Arnuity ElliptaFluticasone Furoate70$22,832
Spiriva HandihalerTiotropium Bromide14$20,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Prempro$25$275,076269 claims
Novo NordiskOzempic$464$167,980145 claims
AbbVieHumira(Cf), Linzess, Creon, Synthroid$18$120,573125 claims
GSKArnuity Ellipta, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta$36$55,973117 claims
Sanofi-aventis U.S. LLCMultaq$64$24,17618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Stevens Point

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →